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Abstract
Cancer cells must rewire cellular metabolism to satisfy the demands of growth and proliferation.
While many of the metabolic alterations are largely similar to those in normal proliferating cells,
they are aberrantly driven in cancer by a combination of genetic lesions and non-genetic factors
such as the tumor microenvironment. However, a single model of altered tumor metabolism does
not describe the sum of metabolic changes that can support cell growth. Instead, the diversity of
such changes within the metabolic program of a cancer cell can dictate by what means
proliferative rewiring is driven, and can also impart heterogeneity in the metabolic dependencies
of the cell. A better understanding of this heterogeneity may enable the development and
optimization of therapeutic strategies that target tumor metabolism.
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INTRODUCTION
The continuous evolution in our understanding of cancer cell biology has served to
demonstrate that cancer is a remarkably complex and heterogeneous collection of diseases
(1). Subsequent to the categorization of cancer types by organ or tissue of origin, one can
further partition neoplastic diversity into an immense number of unique molecular subtypes,
which are marked by varying prognoses, therapeutic regimens, and treatment outcomes (2,
3). Moreover, recent advances in large-scale DNA sequencing and other analytical
technologies (4) have enabled recognition of genomic heterogeneities between histologically
similar tumors, as well as phenotypic variability among cells within a single tumor
population (5–7).
Nevertheless, a series of hallmarks that broadly encompass the distinct biological traits or
capabilities that facilitate tumor growth have been proposed and recently revisited (8). One
such hallmark stems from the seminal observation, initially described nearly a century ago,
that cancer cells exhibit differential aspects of cellular metabolism relative to normal
differentiated cells (9). Advancements over the past decade have shown that several features
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of altered tumor metabolism lie directly downstream of various oncogenes or tumor
suppressors (10, 11), and in some cases may even be selected for during transformation (12).
The initial recognition that cancer cells exhibit atypical metabolic characteristics can be
traced to the pioneering work of Otto Warburg over the first half of the twentieth century
(13–15). In the presence of oxygen, most normal tissues metabolize glucose to pyruvate
through glycolysis, and then completely oxidize a large fraction of the generated pyruvate to
carbon dioxide in the mitochondria through oxidative phosphorylation. Under anaerobic
conditions, normal cells redirect glycolytic pyruvate away from mitochondrial oxidation and
instead largely reduce it to lactate (10). The fundamental paradigm stemming from
Warburg’s studies was that in contrast to normal cells, rapidly proliferating ascites tumors
metabolized glucose to lactate under aerobic conditions despite this process being far less
efficient (~18-fold) in terms of net ATP production per molecule of glucose (10). This
seemingly paradoxical phenomenon, termed the Warburg effect or aerobic glycolysis, has
since been observed across several tumor types and often occurs in parallel with a marked
increase in glucose uptake and consumption, as visualized – and clinically exploited –
through the use of 18F-deoxyglucose-positron emission tomography (FDG-PET) (16).
Though glucose catabolism through aerobic glycolysis has in large part become synonymous
with the hallmark designation attributed to altered cancer metabolism, it alone cannot
explain all the metabolic changes that may be necessary to support the requirements of cell
growth (17). Instead, the importance of glutamine as an additionally critical nutrient in
broadly fueling proliferation has also become better understood and appreciated in recent
years (18).
The significant progress made towards understanding how glucose and glutamine fuel
metabolic rewiring during tumorigenesis has generated optimism that this broad hallmark of
cancer may be exploited through therapeutic intervention (19, 20). However, the
establishment of therapeutic windows that target tumor metabolism may prove difficult
given that normal proliferating cells share similar metabolic requirements and adaptations
(21). Moreover, it has become increasingly clear that while a mode of metabolic rewiring
necessary to support proliferative requirements is a hallmark of cancer, a single conceptual
model of the cancer metabolic program does not exist. Given the incredible biological
diversity across cancer types, the variability among tumors of the same subtype, and the
heterogeneities present within a single tumor, it is not surprising that several metabolic
signatures and distinct dependencies may arise across the spectrum of unique neoplastic
cells.
Indeed, both genetic and non-genetic influences can act to not only facilitate metabolic
flexibility in terms of tumor cell nutrient utilization, but to also potentiate additional
heterogeneous metabolic dependencies or liabilities as well. The continued improvement
and integration of multi-omics strategies, as well as the development of novel in vivo
systems, are now allowing for the advancement of more sophisticated strategies towards
interrogating and better understanding tumor metabolism. Ultimately, such efforts may lead
to the identification of more optimal therapeutic intervention points – and thus the
maximization of therapeutic windows – dependent upon a given metabolic signature.
In this review, we will first discuss the metabolic adaptations that broadly promote cell
growth and how deregulated signaling and transcriptional machinery that may arise during
tumorigenesis can aberrantly modulate such alterations. We will then develop the idea that
while proliferative metabolism is itself a unifying feature of cancer cells in general,
heterogeneities within a given metabolic signature can affect how proliferative
reprogramming is achieved, and impart the cell with a specific set of metabolic
dependencies or liabilities. Finally, we briefly examine how integrated analytical strategies
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should allow for an improved understanding of the complexities that do in fact underlie
metabolic regulation in a context-dependent manner. Throughout this review, we will also
describe the various challenges, efforts, and potential promises in targeting tumor
metabolism as a therapeutic strategy.
THE METABOLISM OF CELL PROLIFERATION
The metabolic program of normal resting cells serves to meet the energetic requirements of
maintaining homeostatic processes through ATP production (22). In contrast, proliferating
cells must not only generate enough energy to support cell replication, but must also satisfy
the anabolic demands of macromolecular biosynthesis and maintain cellular redox
homeostasis in response to escalated production of toxic reactive oxygen species (ROS) (23)
(FIGURE 1). The growth and persistence of tumor cells is also fundamentally dependent
upon generating a metabolic solution that satisfies the sum of these requirements. This
proliferative solution is primarily fueled by glucose and glutamine, as has been presented in
detail by a number of recent excellent reviews (18, 24), and which is described here in brief
summary for context in later discussion.
Nutrient catabolism for cell growth
Most proliferating human cells metabolize glucose by aerobic glycolysis rather than through
the more energetically efficient oxidative phosphorylation used by normal resting cells in
the presence of oxygen (10). An initially proposed misconception was that proliferating cells
harbored mitochondrial impairments and thus relied on fermentative glucose metabolism to
meet their energetic demands. However, it has since been demonstrated that mitochondrial
respiration persists in most proliferating cells, and in turn retains its role as the primary
source of ATP generation (12, 25). Instead, the increased uptake and subsequent preferential
catabolism of glucose to lactate have been proposed to serve more predominantly towards
supporting biomass accumulation and redox maintenance in proliferating cells.
Glycolysis does not lie within a metabolic vacuum in which a single input (glucose) is
converted through a multi-step process into a single output (pyruvate). Rather, this module
of central carbon metabolism is highly interconnected with several other metabolic pathways
– particularly those associated with the de novo synthesis of cellular building blocks –
within which various glycolytic intermediates serve as substrates (24) (FIGURE 2). It has
been noted that under conditions of high glucose uptake, the flux of glycolytic intermediates
into these branching biosynthetic pathways could be substantially increased (26), while
other mechanisms proposed to support this metabolite diversion will be explored in later
sections.
For example, fructose-6-phosphate and glyceraldehyde-3-phosphate may be shunted into the
non-oxidative arm of the pentose phosphate pathway (PPP), resulting in the generation of
ribose-5-phosphate (R5P), which is a critical intermediate in nucleotide biosynthesis.
Alternatively, glucose-6-phosphate can feed into the oxidative arm of the pentose phosphate
pathway (PPP) to generate R5P as well as NADPH, which contributes to the cellular defense
against oxidative stress. The glycolytic intermediate 3-phosphoglycerate (3PG) provides
backbone carbons for multiple nonessential amino acids through its flux into the serine
biosynthesis pathway, while one downstream fate of pyruvate is its transamination to
alanine. Furthermore, reduction of dihydroxyacetone phosphate to glycerol-3-phosphate
effectively provides cells with a critical substrate in the biosynthesis of both phospholipids
and triacylglycerols, while 3PG-derived serine can further feed into phospholipid synthesis
as well (24). Downstream of glycolysis, glucose-derived pyruvate can enter the TCA cycle
and contribute to the production of mitochondrial citrate, which can then feed into de novo
fatty acid synthesis upon its export to the cytoplasm (27).
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Glutamine is the most abundant free amino acid found in human serum. Proliferating cells
use glutamine as the nitrogen donor for biosynthesis of nucleotides, non-essential amino
acids, and hexosamines (18). However, many proliferating cells display a glutamine
dependence that extends beyond these nitrogen requirements. Similar to the examples of
glycolytic branching described above, the TCA cycle also contains intermediates that may
act as substrates in various biosynthetic and NADPH-generating pathways (FIGURE 2).
Proliferating cells are able to sustain the TCA cycle by replenishing these depleted
intermediates through a process called anaplerosis (25). It is well appreciated that glutamine
is an important carbon source for anaplerosis in many proliferating cells, through its
deamidation to glutamate and subsequent entry into the TCA cycle upon glutamate
conversion to α-ketoglutarate (αKG).
Glutamine-derived carbons entering the TCA cycle can, for example, contribute to
mitochondrial citrate production. Following its export to the cytoplasm, citrate can be
converted to acetyl-CoA and oxaloacetate (OAA) by ATP citrate lyase (ACL). While acetyl-
CoA continues the path of exported citrate into fatty acid synthesis as described earlier,
OAA can be further metabolized in a multi-step process to yield αKG and NADPH (25).
Moreover, TCA cycle-derived OAA may be transaminated to aspartate, which can then be
utilized as a carbon source in nucleotide biosynthesis. Finally, glutamine-derived malate can
be exported from the mitochondria and then converted to lactate (glutaminolysis), again with
concomitant production of NADPH. It is worth noting that beyond its function in redox
maintenance, NADPH is also an important reducing agent in multiple biosynthetic pathways
– with a particularly critical role in supporting de novo fatty acid synthesis (28, 29).
Derangement of the circuitry linking cellular signaling and metabolism in cancer
In contrast to prokaryotes and unicellular eukaryotes, mammalian cells are not autonomous
for initiating the alterations necessary to enable a proliferative metabolic program (10).
Instead, normal resting cells typically rely upon growth factor-mediated stimulation of
specific signaling cascades, which in turn trigger a transcriptional response driving the
expression of genes that promote proliferative adaptations (FIGURE 3A). Therefore, despite
exposure to a relatively constant supply of exogenous nutrients, normal resting cells display
far less uptake of such nutrients relative to proliferating cells, and generally preserve an
oxidative metabolism that facilitates maximal ATP production to maintain homeostasis and
survival (10).
As mentioned above, cancer cells and normal proliferating cells share a similar collection of
metabolic demands and adaptations (21, 30). Accordingly, the signaling and transcriptional
circuitry that modulates cell growth (FIGURE 3B) is largely conserved across proliferating
cells in general. However, whereas normal cells possess a variety of checkpoints that enable
correct maintenance of this system, various tumorigenic lesions impart cancer cells with the
ability to fracture proper regulation (FIGURE 3C).
PI3K/Akt/mTORC1 and LKB1/AMPK/mTORC1
Opposing regulatory axes of metabolic rewiring—The PI3K/Akt pathway lies
downstream of receptor tyrosine kinase (RTK) activation and serves an important role in the
tightly controlled regulation of metabolic adaptations that support cell growth (31–33).
Inappropriate activation of this pathway is among the most frequent classes of alterations
seen across several cancers, owing to the vast number of oncogenes and tumor suppressors
identified within this network (34, 35). One downstream effect of PI3K/Akt pathway
activation is the promotion of glycolytic metabolism through Akt-mediated membrane
translocation of glucose transporters, and Akt-dependent activation of hexokinase and
phosphofructokinase (36–39). Additionally, Akt stimulates de novo fatty acid synthesis
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through direct phosphorylation and corresponding activation of ACL (40), which as noted
earlier, catalyzes the conversion of citrate (diverted from the TCA cycle) to acetyl-CoA and
OAA.
Perhaps the most dramatic metabolic consequence of PI3K/Akt stimulation however, is
downstream activation of the cell growth regulator mechanistic target of rapamycin complex
1 (mTORC1) upon Akt-mediated phosphorylation of either of two mTORC1 inhibitors:
tuberous sclerosis 2 (TSC2; part of the TSC1–TSC2 complex) or proline-rich Akt substrate
40 kDa (PRAS40) (41). mTORC1 is the better characterized of two mTOR-containing
multiprotein complexes (the other being mTORC2), and its activation status is affected
through a variety of environmental cues, including growth factors (as transmitted via the
PI3K/Akt pathway for example), energy status (described below), amino acids, and oxygen
levels (41, 42). While mTORC1 can regulate many cellular processes, it remains best known
for elevating protein synthesis through direct phosphorylation of the translational regulators
4E-binding protein 1 (4E-BP1) and S6 kinase 1 (S6K1) (41). Among the downstream targets
of mTORC1-dependent translation are a number of transcription factors (discussed further
below) that coordinate metabolic gene expression: (a) hypoxia inducible factor 1α (HIF1α),
(b) c-Myc, and (c) sterol regulatory element-binding protein 1 (SREBP-1).
The AMP-activated protein kinase (AMPK) is a protein complex that plays a critical role in
regulating the cellular energetic state (43). AMPK senses changes in the cellular ratio of
AMP to ATP, and is activated under conditions of metabolic stress that promote ATP
consumption and/or inhibit ATP production, such as hypoxia or nutrient deprivation. Upon
activation, AMPK stimulates metabolic alterations to limit energy consumption (or enhance
energy production) and thus allow for adaptation to a given metabolic stress (44). For
example, AMPK can deter ATP-consuming fatty acid synthesis through an inactivating
phosphorylation of acetyl-CoA carboxylase (ACC) (45). Moreover, anabolic mTORC1
activity can be suppressed through either of two AMPK-mediated phosphorylation events:
(i) activation of the TSC1/2 complex, or (ii) inactivation of the mTORC1 scaffold protein,
RAPTOR (46, 47). Under conditions of energetic stress, one of the critical upstream
activators of AMPK is liver kinase B1 (LKB1) (48), which is a recognized tumor
suppressor, and illustrates another connection between lesion-induced deregulation of a
signaling axis and metabolic control.
Key transcriptional effectors of proliferative metabolism
HIF-1—Mammalian cells exposed to hypoxia undergo a metabolic response in which
glucose consumption is elevated and glycolytic pyruvate is redirected to lactate, in order to
enable net ATP production by an oxygen-independent mechanism (49). This adaptation is
coordinated by the HIF-1 transcription factor complex, which induces elevated expression of
several genes that support fermentative glucose metabolism, including glucose transporters,
glycolytic enzymes, lactate dehydrogenase A (LDHA), and pyruvate dehydrogenase
kinase-1 (PDK1) (50). The latter two enzymes divert flux of pyruvate to lactate either (i)
directly - LDHA catalyzes conversion of pyruvate to lactate, or (ii) indirectly - PDK1
negatively regulates entry of pyruvate into the mitochondria. HIF-1 activity is dependent
upon stabilization of its HIF-1α subunit. Under normoxic conditions, HIF-1α is suppressed
through post-translational prolyl hydroxylation, which results in von Hippel-Lindau (VHL)
tumor suppressor-mediated proteasomal degradation of HIF-1. However, mTORC1 can
increase the transcription and translation of HIF-1α under normoxic conditions, and
constitutive activation of HIF-1 can occur in tumor cells through a variety of mechanisms,
including (i) loss of VHL, (ii) accumulation of ROS, or (iii) accumulation of the metabolites
succinate or fumarate resulting from loss-of-function mutations in the TCA cycle enzymes
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succinate dehydrogenase (SDH) or fumarate hydratase (FH) (51). This final example will be
revisited later.
Myc—In normal cells, the transcription factor c-Myc (Myc) is important in the regulation of
cell growth and proliferation, and is activated downstream of growth factor-mediated
signaling (52). In several tumors however, Myc is a proto-oncogene that is aberrantly
activated by gene amplification, single nucleotide polymorphisms, chromosomal
translocations (53), or perhaps as a downstream consequence of mTORC1 hyperactivity.
Like HIF-1, Myc stimulates enhanced expression of many genes involved in glucose uptake,
glycolysis, and the fate of glycolytic pyruvate (LDHA). Myc also targets genes that support
the proliferative utilization of glutamine, including glutamine transporters, and genes
involved in both mitochondrial biogenesis and glutaminolysis (23). In fact, Myc-
transformed cells undergo apoptosis in the absence of exogenous glutamine, which is a
critical carbon source for anaplerosis in these cells (54–56). Moreover, Myc also induces the
expression of enzymes in other anabolic pathways, such as serine hydroxymethyltransferase
(SHMT) (serine/glycine metabolism) and fatty acid synthase (FAS) (lipid biosynthesis) (57).
SREBP—SREBP-1 is a member of the SREBP family of transcription factors, and induces
the expression of several genes involved in fatty acid and sterol biosynthesis in response to
growth factors or intracellular sterol levels (58). Recent studies have shown that SREBP-1 is
also a downstream effector of mTORC1 (59, 60), thereby affording mTORC1 with an
additional mode for regulating cell growth. Consequently, hyperactivation of mTORC1
further potentiates the deregulation of de novo lipid synthesis necessary for sustained
membrane production and cell proliferation.
p53—The p53 transcription factor is one of the most vital defenders in the cellular response
to a suite of stresses that may otherwise initiate tumorigenic progression. Activation of p53
induces several pathways that impart anticancer mechanisms, including DNA repair, cell
cycle arrest, and apoptosis (61). Accordingly, p53 is an especially prominent tumor
suppressor, with an estimated 50% of all human cancers harboring either a mutation or
deletion in the TP53 encoding gene. More recently, several lines of evidence have
uncovered a multifaceted role for p53 in metabolic control as well (62). Given the antitumor
regulatory role imparted by p53 in a myriad of other cellular processes, it is unsurprising
that p53 also directs metabolic characteristics consistent with those of normal resting cells.
Namely, this influence lies in affecting glucose metabolism through repression of glycolysis
and concomitant stimulation of oxidative phosphorylation.
For example, p53 transcriptionally induces both synthesis of cytochrome oxidase 2 (SCO2)
(63) and TP53-induced glycolysis and apoptosis regulator (TIGAR) (64), while it represses
expression of various glucose transporters (65), the glycolytic enzyme phosphoglycerate
mutase (66), and PDK-2 (67) – a functionally equivalent isozyme of PDK-1. SCO2 is
required for correct assembly of the cytochrome c oxidase complex (COX) in the
mitochondrial electron transport chain, while TIGAR is a negative regulator of the
glycolytic enzyme phosphofructokinase-1 (PFK1), and thus drives glucose flux through the
ox-PPP for production of ROS-titrating NADPH. Further, p53 may remarkably affect
glucose metabolism in a transcription-independent manner as well, through its direct binding
and inhibition of glucose-6-phosphate dehydrogenase (G6PDH) in the cytoplasm (68).
G6PDH catalyzes the first (and rate-limiting) step in the diversion of glycolytic glucose-6-
phosphate to the ox-PPP. Therefore, its inactivation could contribute to the dampening of
biosynthetic programs, owing to reduction of R5P (nucleotide biosynthesis) and NADPH
(lipid biosynthesis) levels. Indeed, p53-deficient cells exhibited an elevated flux of glucose
into the ox-PPP, along with increases in both NADPH levels and lipogenic rates, relative to
cells expressing wild-type p53 (68). Nonetheless, it is clear that the metabolic control
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imparted by p53 is likely context-dependent and will require additional investigation given
the divergent effects of TIGAR stimulation and G6PDH inhibition in relation to glucose
flux. Finally, it is worth noting that p53 also functions in a positive feedback loop with
AMPK, whereby p53 can transcriptionally enhance the AMPK-dependent cellular stress
response, while AMPK can catalyze the activation-initiating phosphorylation of p53 (69,
70). This p53-AMPK loop can accordingly stimulate catabolic pathways (e.g. fatty acid
oxidation), and – through AMPK-mediated effects on mTORC1 – suppress cell growth.
General therapeutic targeting of the proliferative metabolic program in cancer
Given the recognition that metabolic reprogramming occurs broadly across cancer, the
question of whether facets of tumor metabolism can be therapeutically targeted has garnered
significant attention and investigation. As this matter has been addressed and given excellent
detailed commentaries in a number of recent reviews (19, 20, 71), we will describe a few
key issues here and again briefly revisit the topic in later sections.
One crucial consideration in the development of anticancer therapeutics is to what extent a
given drug can achieve its intended mechanism of action without additionally exerting an
unacceptable toxicity onto normal cells. The establishment of this “therapeutic window” is
especially challenging in the context of targeting various metabolic adaptations that support
rapid cell growth because of their relative conservation in properly regulated proliferating
cells.
Nonetheless, some of the first chemotherapeutic agents developed – nucleoside analogues
referred to as antimetabolites – target nucleotide biosynthesis through the direct inhibition of
enzymes used in DNA synthesis (71), and have remained a common and effective
component of treatment regimens administered across several types of cancer. However,
because their targets are not exclusive to tumor cells, these compounds have somewhat
expectedly been linked to toxicities that stem from the unintended effects they exert on non-
malignant proliferating cells.
Another therapeutic opportunity that has been explored is the small molecule inhibition of
key enzymes involved in metabolic pathways such as glycolysis and fatty acid synthesis. In
most cases, the potential for this strategy has stemmed from preclinical studies in which
tumor cell proliferation was negatively affected by small molecule or RNAi-mediated
knockdown of a particular target enzyme either in vitro or in xenograft models (19). It
remains to be determined in most cases whether the potential yielded from these results will
remain durable upon downstream evaluation of therapeutic windows that are attainable from
the inhibition of enzymes that are likely of similar importance in normal proliferating cells.
For example, the glucose analog 2-deoxyglucose (2DG) is a glycolytic inhibitor that has
been previously tested as an anticancer agent in phase I clinical trials. Although sufficient
amounts of 2DG can potentiate cancer cell arrest and/or death by limiting glucose
catabolism, the dosing necessary to achieve such effects in patients resulted in adverse
toxicity (19).
DECIPHERING METABOLIC HETEROGENEITY
In line with the complexity that differentiates cancer into a largely heterogeneous collection
of diseases, it has become clear that a single metabolic program cannot be used to globally
define altered tumor metabolism. Instead, though rapid cell growth is a general neoplastic
feature, variability within the underlying metabolic rewiring of a given cancer cell can
dictate not only how proliferative adaptations are driven, but can also confer heterogeneity
in the metabolic dependencies of the cell. This diversity may in part clarify why some small
molecule compounds, such as antimetabolites and mTOR inhibitors (19, 71), don’t elicit a
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more general therapeutic efficacy despite the requirement of all malignant cells to promote
elevated nucleotide biosynthesis, or the prevalence of mTORC1 hyperactivity in many
tumor types.
Ultimately, efforts to unravel metabolic heterogeneity and flexibility may enable the
identification of novel therapeutic targets, and as importantly, reveal the metabolic
signatures in which intervention through a specific target is most beneficial in terms of
potentiating tumor cell death while affording the maximal therapeutic window.
Though cell proliferation is predominantly fueled by glucose and glutamine, the precise
extent of their uptake and utilization can vary substantially across different tumors. While
ATP generation is broadly attributed to mitochondrial respiration in cancer cells for
instance, both cell type and conditional context can affect glycolytic contributions to ATP
production by up to two orders of magnitude (72). Tumors also exhibit variable uptake of
glutamine and other metabolites such as 18F-labeled amino acid analogues, and display
differential levels of lactate secretion (16, 24, 73, 74).
Toward this end, it was recently reported that exogenous glutamine dependence varies
across different breast tumor subtypes, as determined by lineage-specific expression of the
enzyme glutamine synthetase (encoded by the gene GLUL) (75), which catalyzes the
synthesis of intracellular glutamine from glutamate. Another study revealed that glucose-
fueled anaplerosis may be the preferred means of replenishing TCA cycle intermediates in
some glutamine-independent cancer cell lines, and can also function as a compensatory
anaplerotic mechanism in glutaminase-suppressed glutamine-addicted cell lines (76). This
glucose-dependent maintenance of the TCA cycle was mediated by the enzyme pyruvate
carboxylase (PC), which catalyzes the carboxylation of pyruvate to OAA, and it was those
glutamine-addicted cell lines that displayed elevated PC activity that could sustain growth
when glutamine-dependent anaplerosis was not an option. Thus, it is becoming clearer that
variability exists across different cancers in terms of the glycolytic and glutaminolytic
contributions to malignant proliferation, and moreover, that tumors may harbor some extent
of metabolic flexibility that allows for the utilization of different anaplerotic precursors or
metabolic platforms as a means of dynamic adaptation under stress. Such adaptive strategies
could therefore also be considered in the development and optimization of therapies
targeting tumor metabolism.
Heterogeneities also exist in the regulation of lipid metabolism in transformed cells. While
glucose and glutamine serve as the primary catabolic substrates of proliferative metabolism,
fatty acid oxidation (FAO) can also be used as an additional (or alternative) energy source in
some leukemia cells and lung tumors (77, 78). In addition, monoacylglycerol lipase
(MAGL)-catalyzed hydrolysis of monoacylglycerols may play a role in providing a source
of free fatty acids in some higher-grade tumors (79), which would expand the source of free
fatty acids in these cells beyond the more typically attributed de novo fatty acid synthesis
pathway. Lipidomics analysis further suggested that elevated MAGL activity was
particularly responsible for the increased production of specific lipid messengers, such as
lysophosphatidic acid (LPA) and prostaglandin E (PGE2) (79), which have been shown to
promote tumor cell aggressiveness (80, 81). This result suggests that the deregulation of
lipid metabolism extends beyond the commonly noted elevation of lipogenic enzyme levels
(ACL, ACC, FAS) (82), and offers the possibility that distinct mechanisms of fatty acid
production feed into different downstream pathways.
Metabolic enzymes as oncogenes or tumor suppressors
Glycolytic and oxidative ATP contributions can vary widely between different cancer cells,
but mitochondrial activity is generally preserved. Nonetheless, there are examples for which
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mutations in TCA cycle enzymes have been identified in specific cancers, and these lesions
potentiate tumorigenic insults whose mechanisms are now becoming better understood
(FIGURE 4A). Loss-of-function germline mutations in SDH and FH have been recognized
for over ten years to occur in certain cases of: (i) paraganglioma and pheochromocytoma
(SDH), and (ii) leiomyoma and certain cases of renal cell carcinoma (FH) (reviewed in
(83)). Ensuing studies revealed that HIF-1 levels were elevated in SDH- and FH-deficient
tumors, and could thus elicit transcriptional activation of genes promoting fermentative
glucose metabolism even under normoxic conditions. The mechanism underlying this effect
was ultimately linked to the accumulation of succinate or fumarate stemming from
inactivation of SDH or FH, respectively. Both succinate and fumarate were found to enable
aberrant stabilization of HIF-1α through competitive inhibition of prolyl hydroxylase 2
(PHD2) (or PHD3) (84–86), which otherwise suppresses this stabilization under normoxic
conditions by marking HIF-1 for VHL-mediated ubiquitination. Therefore, in the cancer
types noted above, SDH and FH can genetically act as tumor suppressors.
More recently, whole-genome sequencing efforts led to the identification of recurrent
mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 in a fraction of gliomas, acute
myeloid leukemias, and chondrosarcomas (87–89). However, unlike the SDH and FH
examples above, IDH mutations are somatically acquired and don’t strictly abolish the wild-
type function of IDHs, which normally catalyze the decarboxylation of isocitrate to αKG.
Instead, IDH mutants acquire the neomorphic ability to reduce αKG to 2-hydroxyglutarate
(2HG) – a metabolite that is present only at trace levels under normal conditions (90).
Collective evidence stemming from several reports have highlighted that the
pathophysiological role of 2HG is, at least in part, the competitive inhibition of various
αKG-dependent dioxygenases, including TET2 DNA hydroxylases and JmjC histone
demethylases (91, 92). Therefore, the tumorigenic effect linked to IDH mutations appears in
part to be at the level of epigenetic deregulation. For example, tumor-associated IDH
mutations are sufficient to block the differentiation of non-transformed cells through 2HG-
mediated inhibition of histone demethylation (93). Further, the introduction of mutant IDH1
into primary human astrocytes can trigger remodeling of the DNA methylome in a fashion
that recapitulates patterns similarly observed in mutant IDH-harboring glioma cells (94).
Similarly, conditional knock-in mice in which the most common IDH1 mutant (R132H) was
expressed in myeloid-lineage hematopoietic cells, showed among a number of alterations,
changes in DNA methylation similar to those seen in IDH-mutant AML (95). Interestingly,
recent evidence has further suggested that the accumulation of both succinate and fumarate
that arise in SDH- and FH-deficient tumors respectively (as described above), may also
inhibit various αKG-dependent dioxygenases, resulting in analogous deregulation of
epigenetic modifications (96). An additional report described an enantiomer-specific
mechanism by which (R)-2HG, but not (S)-2HG, stimulated EGLN prolyl hydroxylase
activity and consequent HIF-1α degradation (97). (R)-2HG-mediated elevation of EGLN
activity promoted the growth and proliferation of human astrocytes, and this result may
explain why IDH-mutated adult tumors seem to select for the (R)-2HG enantiomer. At this
point, it appears that 2HG-mediated effector functions are complex and seemingly extend
beyond induced deregulation of epigenetic signatures. Further investigation into the
mechanisms potentiated by SDH, FH, and IDH1/2 mutations may uncover a context-
dependence for 2HG function, inhibition of various αKG-dependent dioxygenases, and the
role of HIF-1α stabilization in these particular tumors. Nonetheless, 2HG may serve as a
useful biomarker in disease monitoring, and the development of small molecule inhibitors
specific to mutant IDH1/2 could be an attractive treatment strategy given the potential
therapeutic window afforded by tumor-specific expression of the neomorphic enzymes.
The recognition that metabolic enzymes can genetically behave as tumor suppressors (SDH,
FH) or oncogenes (IDH1/2) in certain cancer subsets has been extended over the past year to
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include two additional examples in which tumorigenic effects are linked to genome-level
alteration of a metabolic gene (FIGURE 4B).
A fraction of malignant breast and melanoma cells are dependent on elevated expression of
phosphoglycerate dehydrogenase (PHGDH), which catalyzes the conversion of 3-
phosphoglycerate to 3 phosphohydroxypyruvate in the first step of the serine biosynthesis
pathway (98, 99). The PHGDH gene is commonly amplified within a number of these
tumors, leading to elevated PHGDH protein expression. Increases in PHGDH expression at
both the mRNA and protein levels were observed in nearly 70% of estrogen receptor (ER)-
negative breast cancers, despite the lack of PHGDH amplification among a fraction of cell
lines within this subtype (99). Cell lines that exhibited PHGDH overexpression displayed
increased flux of glucose carbon through the serine biosynthesis pathway branching from
glycolysis (98, 99). Further, RNAi-mediated suppression of PHGDH in cell lines designated
as having increased levels of the enzyme, but not in those lacking such status, resulted in a
marked decrease in cell growth and reduced serine synthesis. Strikingly, suppression of
PHGDH in the knockdown-sensitive breast cell lines did not affect intracellular serine
levels, but rather, caused a reduction in αKG levels (99). In fact, the serine pathway was
responsible for nearly 50% of the net conversion of glutamate to αKG for glutamine-driven
anaplerosis in PHGDH-overexpressing cells. The results illustrated by these studies suggest
a potential utility in the therapeutic inhibition of PHGDH in those cancers that express
elevated levels of the enzyme.
Another recent report described the identification of a molecular signature for the tumor
initiating cells (TICs) of non-small lung cancer (NSCLC) (100). Among the signature
features described was overexpression of glycine decarboxylase (GLDC) – a component of
the glycine cleavage system – relative to NSCLC cells lacking the TIC-status marker
specified in the study, and thus demonstrates an example of intratumor metabolic
heterogeneity. The RNAi-mediated knockdown of GLDC effectively diminished
proliferation and tumorigenicity in the lung cancer TICs, whereas analogous effects were not
observed upon similar treatment in normal human lung fibroblasts. Moreover, GLDC
overexpression was identified across a variety of other tumor types, and remarkably,
overexpression of active GLDC alone could induce transformation of 3T3 cells in vitro and
promote tumor formation from these same cells in vivo. Metabolomics profiling revealed
that among the alterations driven by enhanced GLDC expression was an increase in
pyrimidine biosynthesis – an effect that imparted elevated sensitivity of GLDC-
overexpressing cells to treatment with low doses of methotrexate, with minimal effects seen
in control cells. Perhaps additional investigation will determine whether GLDC
overexpression can be more broadly used as a predictor of antifolate sensitivity, thus
informing for contexts in which these chemotherapeutics may enjoy a greater therapeutic
window. The methotrexate result further suggests a possible route of increased therapeutic
efficacy through the synergistic use of antifolates with a GLDC inhibitor for treatment of
relevant GLDC-overexpressing tumors.
Systemic depletion of tumor-essential amino acids
Altered tumor metabolism need not consist entirely of changes or adaptations that are driven
to satisfy the demands of cell growth and proliferation. Instead, metabolic rewiring during
tumorigenesis may also result in the development of specific metabolic liabilities that, while
likely not selected for nor acting to promote proliferation, still arise as additional
dependencies that must be met to maintain cell survival. In particular, several tumor types
are auxotrophic for one or more amino acids owing to deficiencies in a corresponding
endogenous biosynthesis or salvage pathway (101). Consequently, these cells have a
particular reliance on the import of a given amino acid(s) from the extracellular serum pool.
Extensive in vitro, in vivo, and clinical evaluations conducted over the past sixty years have
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established that this type of metabolic liability can be exploited through enzyme-mediated
systemic depletion of a circulating “tumor-essential” amino acid, resulting in the selective
starvation and death of targeted auxotrophic malignant cells with minimal effect on normal
cells (101).
The most notable example of this strategy in a therapeutic setting is certainly the success of
L-Asparaginase in the treatment of acute lymphoblastic leukemia (ALL) (102). Whereas
normal cells can endogenously synthesize the non-essential amino acid L-asparagine (L-
Asn) through the catalytic action of asparagine synthetase (ASNS), certain ALL
lymphoblasts lack or express very low levels of ASNS and therefore require uptake of serum
L-Asn (103–105). The enzyme L-Asparaginase catalyzes the hydrolysis of L-Asn to L-
aspartate (L-Asp) and ammonia, resulting in depletion of ALL-essential L-Asn from the
extracellular pool, which subsequently induces selective apoptosis of the auxotrophic
lymphoblasts (106, 107). Though initially evaluated for clinical efficacy as a single agent,
Escherichia coli L-Asparaginase II (EcAII) has since become a standard component in a
combination chemotherapy regimen that now provides a remarkable survival rate in
pediatric ALL, but still garners further optimization for the treatment of adult ALL (108,
109). While EcAII is currently approved for use in the front-line treatment of ALL, other
cancer types (e.g. certain adult non-Hodgkin’s lymphomas (110) and ovarian carcinomas
(111)) have since been shown to have a similar dependence on the uptake of serum L-Asn as
well. EcAII can also hydrolyze glutamine, though at efficiencies considerably lower than
those observed for L-Asn deamidation (112). However, the clinical implications and utility
of EcAII-mediated glutamine degradation remain unclear. While glutamine depletion could
enhance the efficacy of EcAII given the critical role of glutamine as a proliferative fuel,
others have suggested that glutamine hydrolysis may instead contribute to clinical toxicities
associated with EcAII administration (113).
It is worth noting that while ASNS transcript level has acted as the historical predictor of
ALL sensitivity to EcAII treatment, a number of studies over the past decade have
alternatively demonstrated that additional ASNS-independent genetic and metabolic
determinants may also contribute to EcAII efficacy (114–116). One example is described
through the correlation between ASNS expression and asparaginase sensitivity in patients
either harboring or lacking the t(12;21)(p13;q22) chromosomal translocation, which results
in expression of the TEL-AML1 fusion protein. This chromosomal alteration occurs in
approximately 25% of pediatric B-cell lineage ALL cases (117). Although ASNS expression
was expectedly correlated with asparaginase sensitivity in TEL-AML1-negative patients, a
similar pattern was absent in the converse TEL-AML1-positive cohort (118). Strikingly,
while TEL-AML1-positive patients were generally more sensitive to asparginase treatment,
one report showed that samples isolated from these patients exhibited nearly 5-fold greater
levels of ASNS mRNA relative to TEL-AML1-negative patients and healthy controls (119).
Therefore, while native EcAII received FDA approval nearly forty years ago, the
mechanisms dictating its efficacy are still not entirely understood.
Another emergent example that highlights the therapeutic exploitation of a tumor-specific
amino acid dependency stems from the recognition that a large fraction of hepatocellular
carcinomas, metastatic melanomas, and renal cell carcinomas express low levels of the
enzyme argininosuccinate synthetase (ASS) or harbor other urea cycle defects that render
the host malignant cells auxotrophic for L-arginine (L-Arg) (120). Two arginine-degrading
enzymes (bacterial arginine deimidase (ADI) and human arginase I) have since been
evaluated in various xenograft models and/or early phase clinical trials for their ability to
inflict selective toxicity upon urea cycle-defective tumors, with promising results to date
(101, 121). The systemic depletion of L-Arg as a therapeutic strategy is of particular interest
because the prognoses for malignant melanomas and hepatocellular carcinomas are
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generally poor, given the difficulty in treating these aggressive tumors with conventional
chemotherapeutics (120).
Unraveling selective expression of metabolic enzymes
It is well recognized that many metabolic reactions can be effectively catalyzed by multiple,
distinct members of a given enzyme family, albeit with some level of variability in kinetic
efficiency. Moreover, members of the same enzyme family can possess other distinguishing
molecular or biochemical characteristics that extend beyond catalysis of the otherwise
unifying reaction. This diversity arises through either: (i) expression of functionally similar
enzymes encoded by different genes, or (ii) post-transcriptional alternative splicing from a
single encoding gene. It has become increasingly appreciated that cancer cells preferentially
express specific members of a metabolic enzyme family in either a broad or context-
dependent manner.
For instance, some cancers such as glioblastoma multiforme (GBM) exhibit increased
expression and/or reliance on hexokinase 2 (HK2) (122, 123). Hexokinase catalyzes the
phosphorylation of glucose to glucose-6-phosphate in the initiating step of glycolysis. In
general, HK2 expression is restricted to skeletal and muscle tissues, while normal brain and
lower-grade gliomas for example, predominantly express HK1. Perhaps the elevated
expression of HK2 in some tumors is indicative of this particular HK imparting some
additional functional role necessary in the context of these malignancies.
Downstream of HK in the glycolytic pathway is the enzyme PFK1, which catalyzes the rate-
limiting conversion of fructose-1-phosphate to fructose-1,6-bisphosphate. PFK1 is a target
of positive allosteric regulation by the metabolite 2,6-fructose bisphosphate (F2,6P), whose
intracellular levels are modulated in part by PFK2. Most members of the PFK2 family have
dual kinase and phosphatase activity, and can therefore catalyze the generation or depletion
F2,6P, depending on the ratio of the two activities (124). Accordingly, the four identified
PFK2 enzymes are more appropriately designated as PFKFB1–4 to reflect the additional
F2,6Pase activity. The PFKFB3 isozyme has almost negligible phosphatase activity and can
therefore activate PFK1 to promote flux through glycolysis. PFKFB3 is highly expressed in
many cancers (125), and its small molecule-mediated inhibition was shown to induce a
cytostatic effect in RAS-transformed cells (126).
In contrast to PFKFB3, the PFKFB4 isozyme has a greater phosphatase to kinase activity
ratio and can therefore affect a shunt of glucose-6-phosphate flux into the PPP by decreasing
PFK1 activity. It was recently reported that PFKFB4 is essential to the survival of certain
prostate cancer cell lines because its modulation of F2,6P levels was critical for the
maintenance of redox homeostasis in these cells (127). In fact, while PFKFB4 depletion in
prostate cancer cell lines induced a large increase in ROS and subsequent cell death, similar
PFKFB4 silencing in normal human prostate epithelial cells had little effect on ROS levels
and cell growth.
Glutaminase-catalyzed deamidation of glutamine to glutamate is a key step in both
glutaminolysis and synthesis of ROS-scavenging glutathione (GSH). There are two
predominant human isozymes of glutaminase: kidney-type (GLS1) and liver-type (GLS2)
that, despite sharing some functional similarities, are regulated quite differently (128, 129).
Whereas Myc specifically potentiates elevated expression of GLS1 and promotes the
downstream utilization of glutamine carbon in anaplerosis (55, 56), p53 specifically
activates GLS2 to support cellular defense against oxidative stress (130). It is thus likely that
GLS1 and GLS2 have different roles in tumorigenesis as well. For example, GLS2 levels are
markedly decreased in hepatocellular carcinoma relative to normal liver tissues, while GLS2
overexpression in tumor cells reduced colony formation (130). Moreover, an in vivo model
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of Myc-transformed hepatocellular carcinoma demonstrated that progression from the
pretumor to tumor state was marked with changes in the expression of several genes,
including a considerable downregulation of GLS2 and substantial upregulation of GLS1
(131). Additional lines of evidence have further described a link between GLS1 inhibition
and the growth suppression of various cancer cells (e.g. lymphoma, breast) as well (132–
134). The sum of these results suggest that selective inhibition of GLS1 may provide a
tractable treatment approach (135), though the corresponding attainable therapeutic window
will likely be context-dependent.
The most extensively studied example of selective isoform expression described to date
focuses on the enzyme pyruvate kinase (PK), which catalyzes the final irreversible step of
glycolysis – conversion of phophoenolpyruvate (PEP) to pyruvate with concomitant
generation of ATP. There are four members of the PK family in mammals: PKL and PKR
are splice variant isoforms encoded by the PK-LR gene, and PKM1 and PKM2 are splice
variant isoforms encoded by the PK-M gene. Products of the PK-LR gene are normally
restricted to expression in the liver (PKL) and red blood cells (PKR). The M1 and M2
isoforms differ by a single exon and share ~96% sequence identify at the amino acid level.
Nonetheless, PKM2 is the major PK isoform expressed in an essentially universal fashion
across all proliferating cells evaluated to date (30, 136). Moreover, PKM2-expressing cells
show a selective growth advantage relative to PKM1-expressing cells as evaluated in
xenograft models (137), despite the seeming paradox that PKM2 possesses lower specific
PK activity relative to PKM1 (138). However, whereas PKM1 is constitutively active,
PKM2 can be negatively regulated through its binding to tyrosine-phosphorylated proteins
downstream of cellular kinase signaling (139). One prominent hypothesis for rationalizing
the selective expression of PKM2 in proliferating cells is that its propensity for modulation
enables cellular tuning of glycolytic intermediate flux into branching anabolic pathways
rather than to pyruvate (24). It was further reported recently that elevated levels of ROS
could inactivate PKM2 in a human lung cancer cell line (140). This additional regulatory
mechanism could promote diversion of glycolytic flux into the PPP as a means to generate
NADPH for combatting oxidative stress. Remarkably, PKM2-expressing cells also
paradoxically generate more glucose-derived lactate relative to cells expressing PKM1
(137). A potential resolution to this observation may lie in a recently described alternative
glycolytic pathway in which PEP conversion to pyruvate could be catalyzed without the
corresponding generation of ATP that marks the PK-mediated catalysis of this conversion
otherwise (138).
One complicating factor in further understanding the selection for PKM2 in proliferating
cells stems from a recent study, which while confirming PKM2 as the major PK expressed
in primary tumor tissues and cell lines, further offered evidence suggesting that PKM2 was
also the predominant isoform expressed in matched control tissues and normal cell lines
(141). This result presents disparity to a commonly cited model that proposes a PK isoform
“switch”, whereby normal differentiated cells specifically select for PKM1 expression, but
shift to expression of PKM2 upon rewiring to a proliferative metabolic program (136). It is
worth noting however, that while PKM2 is not necessarily selected for specifically in
proliferating cells, the expression of PKM1 in such cells is essentially absent or detected at
only very low levels (141).
PKM2 may have roles beyond that of its regulated PK activity. In particular, a number of
non-metabolic activities mediated by PKM2 upon translocation to the nucleus have been
described, including the transactivation of β-catenin (142) and HIF1 (143). Moreover,
modulation of active tetrameric PKM2 to its inactive dimeric form may impart proliferative
advantages beyond those described earlier. The dimeric form of PKM2, which is
predominantly nuclear-localized in highly proliferative tumor cells, can remarkably act as a
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protein kinase that catalyzes phosphorylation of the STAT3 transcription factor,
subsequently leading to the elevated expression of cancer-relevant genes such as MEK5
(144). Certainly, much remains to be unraveled in terms of how the glycolytic and non-
glycolytic functions PKM2 may be balanced, regulated, and manipulated in both
differentiated and proliferating cells. Interestingly, inhibitors and activators of PKM2 are
each being explored as therapeutic points of intervention (19).
Non-genetic contributions to tumor metabolism
Altered tumor metabolism is not simply the final outcome of some combination of cell-
autonomous genetic alterations. Instead, a non-genetic component in the form of the tumor
microenvironment must additionally be considered as a component in the equation that
influences metabolic changes in cancer cells (7). Solid tumors are poorly vascularized, and
therefore their surrounding environment can subject distinct regions of the tumor to spatial
and temporal gradients of oxygenation, pH, and nutrient availability (145). Consequently,
metabolic alterations are likely also stimulated to some extent as a means for a given tumor
cell to adapt to these dynamic and energetically stressful conditions.
The relationship between genetic and non-genetic determinants in the regulation of tumor
cell metabolism appears to be complex and not simply one of cause and effect. For example,
fluctuating oxygen gradients across the microenvironment can drive sporadic hypoxia, the
stabilization of HIF-1α, and a corresponding induction of the HIF1-induced transcriptional
program (50). Regardless of whether HIF-1-induced transcriptional effects are promoted
through inappropriate genetic regulation or in response to hypoxic stress, one of its
downstream consequences remains the conversion of a large percentage of glycolytic
pyruvate to secreted lactate. The secreted lactate in turn triggers additional metabolic
responses as a result of local acidification within the tumor microenvironment. It has also
been suggested that this lactate-driven acidification can promote both tumor invasion and
immune evasion (146, 147), which are among the other denoted hallmarks of cancer (8).
Moreover, lactate secretion may have a functional role within a larger system of metabolic
cooperation and symbiosis between cells in the microenvironment. Described as a “two-
compartment” model of tumor metabolism, the symbiosis is characterized as the potential
for anabolic malignant cells to extract high-energy metabolites (e.g. lactate, glutamine, fatty
acids) from adjacent catabolic cells (within the tumor or neighboring stromal cells) through
a network of nutrient sharing that can stimulate tumor proliferation and metastasis (148,
149). Studies reporting two-compartment tumor metabolism have recently emerged in the
context of breast cancer cells and their neighboring fibroblasts (150, 151), as well as for
ovarian cancer cells and their neighboring adipocytes (152). A further understanding of this
concept may lead to the development of therapies that inhibit this process of energy transfer
in the tumor microenvironment, and could demonstrate one example of a means to
overcome potential barriers posed by intratumor heterogeneity in targeting cancer cell
metabolism.
Non-genetic factors may also have additional roles in affecting energy metabolism. Under
hypoxic conditions, several cell lines utilize glutamine carbon as the major source of de
novo lipogenesis through the reductive carboxylation of glutamine-derived αKG (153, 154).
This IDH-mediated process generates isocitrate, which is then isomerized to citrate, thus
effectively redirecting the traditional direction of the TCA cycle. Glutamine-fueled reductive
carboxylation of αKG serves a similar role in cells harboring defective mitochondria (155),
which would possess a comparable impairment in glucose-dependent lipogenesis. In another
study, the interplay between oncogenic alteration and tumor tissue of origin was shown to
influence a differential utilization of glucose and glutamine as proliferative fuels (156).
While MET-transformed murine liver tumors were marked by increased glucose
metabolism, little glutaminolysis and net glutamine synthesis, Myc-induced liver tumors
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exhibited significant increases in both glucose and glutamine catabolism. Further, Myc-
induced lung tumors displayed increases in both glucose and glutamine catabolism,
however; similar to MET-driven liver tumors, had a net accumulation of glutamine.
TECHNOLOGICAL ADVANCEMENTS TO STUDY TUMOR METABOLISM
Tumor metabolism is proving to be a general term used to describe a complex collection of
diverse metabolic signatures, comprised of various metabolic changes that arise as an overall
response to some combination of genetic and non-genetic determinants. This metabolic
program must, by definition, satisfy the multiple demands of cell proliferation; however,
there is some degree of heterogeneity in the precise collection of metabolic dependencies
and liabilities within a given tumor cell.
Recognition of this complexity has in large part been aided by the progress of various
omics-based strategies over the past decade. Ideally, the continued exploitation and
integration (FIGURE 5) of these approaches will result in the identification of novel or
context-dependent therapeutic targets that optimally balance drug efficacy and therapeutic
window. Moreover, efforts to model tumor metabolism in vivo should better mimic
physiological conditions that are met in clinical settings, and may afford the development of
new approaches to in vivo metabolic analysis. In addition to several examples cited
throughout this review, two recent studies have further demonstrated the power of
integrative approaches and in vivo modeling in the study of tumor metabolism going
forward.
In one example, a pancreatic ductal adenocarcinoma (PDAC) mouse model was utilized and
integrated with downstream biochemical, transcriptomic, and metabolomics analyses to
determine the mechanisms by which the KRasG12D lesion promoted tumor maintenance
within this particular carcinoma (157). It was ultimately determined that KRasG12D had an
important role in altering glucose metabolism in PDAC, namely by stimulating glucose
uptake and promoting diversion of its flux from glycolysis to branching anabolic pathways.
In the other example, mouse models of genetically diverse primary human glioblastoma
(GBM) were each infused with 13C-labeled nutrients to ultimately allow for evaluation of
the mechanisms by which these tumors were fueled (158). One finding was that flux through
the pyruvate dehydrogenase complex (PDH) was the major source of carbon flux into the
TCA cycle, despite a prior proposal that PDH was suppressed in high-grade tumors (159).
This observation served to perhaps indicate that differences in metabolism could stem from
whether evaluation was conducted using an in vivo system versus in the context of cultured
cell lines. Additionally, glucose uptake and oxidation did not appear to vary among GBM
tumors with distinct oncogenic driver mutations, further implicating complexities in tumor
metabolism that in part lie beyond genomic footprints.
CONLCUSIONS
The collection of advances made in our understanding of tumor metabolism in recent years
has not only afforded a better understanding of the metabolic changes that help satisfy
proliferative demands, but as critically, has revealed the diversity of mechanistic inputs and
context-dependent determinants that can drive metabolic rewiring. Moreover, numerous
studies have illustrated that metabolic adaptations can in fact be selected for during
transformation as well.
While the general uniformity of altered tumor metabolism lies in the shared ability of
neoplasms to induce adaptations that stimulate rapid cell growth, we are now recognizing
that the metabolic signature of cancer cells is one marked by the same complexities and
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diversity that characterize the disease as a whole. Namely, we are now beginning to unravel
the heterogeneities that exist within the metabolic program of tumors that arise from
different tissues, among different tissue subtypes, and even between cells populating a single
tumor.
Our understanding of tumor metabolism continues to evolve as advances in several
analytical technologies and modeling strategies are affording the implementation of
systems-level and integrated strategies for use in metabolic studies. Ultimately, these efforts
will ideally facilitate further progress in capitalizing upon the exploitation of atypical
metabolic features in cancer as a means of therapeutic intervention. Deciphering the
interplay between genetic and non-genetic components that together contribute to metabolic
reprogramming in a given setting, may serve as the critical factor in determining therapeutic
targets that enable maximal drug efficacy with minimal deleterious effect on normal cells
(FIGURE 6).
Indeed, altered metabolism appears to constitute a unique hallmark of cancer. However, now
we must embrace, dissect, and improve upon our understanding of the variability that exists
beneath this encompassing designation.
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STATEMENT OF SIGNIFICANCE
Altered tumor metabolism is now a generally regarded hallmark of cancer. Nevertheless,
the recognition of metabolic heterogeneity in cancer is becoming clearer as a result of
advancements in several tools used to interrogate metabolic rewiring and dependencies.
Deciphering this context-dependent heterogeneity will supplement our current
understanding of tumor metabolism and may yield promising therapeutic and diagnostic
utilities.
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FIGURE 1. Metabolism: Resting versus Proliferating cells
Normal resting cells employ a catabolic metabolism to satisfy the energetic requirements of
homeostasis. This demand is met through fatty acid oxidation and the oxidative metabolism
of glucose.
Proliferating cells however, must rewire their metabolic program to not only meet various
energetic requirements, but to also satisfy the anabolic demands of macromolecular
biosynthesis (nucleotides, lipids, proteins), as well as the maintenance of redox homeostasis.
Upon growth factor-mediated stimulation, proliferating cells increase their uptake of glucose
and glutamine, which are the two primary substrates that fuel cell growth. Solid arrows are
indicative of increased cellular uptake.
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FIGURE 2. Glucose and Glutamine Fuel Proliferation
Proliferating cells must satisfy three metabolic demands: (i) bioenergetics, (ii)
macromolecular biosynthesis, and (iii) redox maintenance. The metabolic program of these
cells is marked by an increased uptake of glucose and glutamine, and subsequent utilization
of these two substrates to support cell growth. Most imported glucose is metabolized to
lactate through aerobic glycolysis, although this process is a far less efficient means of ATP
production relative to oxidative metabolism. However, the preferential catabolism of
glucose to lactate allows proliferating cells to shunt various glycolytic intermediates (blue
dots) into branching anabolic pathways that support additional metabolic requirements.
Glutamine serves as a nitrogen source for the biosynthesis of nucleotides and various non-
essential amino acids. In addition, glutamine is an important carbon source for the
replenishment of TCA cycle intermediates (green dots), which are diverted into various
anabolic pathways during proliferation. Further detail is found in the main body of the text.
G6P – glucose-6-phosphate. F6P – fructose-6-phosphate. GADP – glyceraldehyde-3-
phosphate. DHAP – dihydroxyacetone phosphate. 3PG – 3-phosphoglycerate. αKG – α –
ketoglutarate. OAA – oxaloacetate. N – nucleotide biosynthesis. L – lipid biosynthesis. AA
– amino acid biosynthesis.
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FIGURE 3. Signaling and transcriptional machinery that regulate metabolism
A. The PI3K/Akt axis can be activated downstream of RTK activation or as a downstream
effector of activated Ras. PTEN is a negative regulator of the PI3K/Akt pathway. mTORC1
can become activated upon Akt-mediated phosphorylation of either of two mTORC1
inhibitors: TSC2 (part of the TSC1-TSC2 complex) or PRAS40. Conversely, mTORC1
activity can be suppressed through AMPK-mediated phosphorylation of either TSC2 or
RAPTOR. Finally, amino acids can activate mTORC1 by modulating the nucleotide loading
states of Rag GTPases, which form obligate heterodimers consisting of RagA or RagB with
Rag C or Rag D. Further description of amino acid-dependent activation of mTORC1 and
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the additional molecular components of this pathway are reviewed elsewhere (41). AMPK
itself is activated by the upstream kinase LKB1. Among the downstream targets of
mTORC1-dependent translation are the transcription factors HIF-1, Myc, and SREBP-1.
HIF-1 stabilization is repressed by VHL under normoxic conditions. p53 also has a
multifaceted role in metabolic control, which includes involvement in a positive feedback
loop with AMPK.
RTK – receptor tyrosine kinase. PTEN – phosphatase and tensin homolog. PI3K –
phosphatidylinositol-3-phosphate kinase. LKB1 – liver kinase B1. AMPK – AMP-activated
protein kinase. TSC – tuberous sclerosis complex. mTOR – mechanistic target of rapamycin.
VHL – von Hippel-Lindau. SREBP – sterol regulatory element-binding protein. HIF –
hypoxia-inducible factor.
B. HIF induces the expression of various glucose transporters and glycolytic enzymes, and
promotes the flux of pyruvate to lactate. Myc affects glucose metabolism in a similar
manner to HIF. Additionally, Myc stimulates the expression of glutamine transporters, and
promotes mitochondrial biogenesis and entry of glutamine carbon into the TCA cycle.
SREBP-1 induces the expression of several genes involved in fatty acid synthesis. p53
affects glucose metabolism through repression of glucose transporters and glycolytic
activity, while also transcriptionally promoting oxidative phosphorylation. Akt promotes
membrane translocation of glucose transporters and the activation of various glycolytic and
fatty acid synthesis enzymes.
Dashed arrow: transcription-mediated effect
C. Various components of the signaling and transcriptional network can genetically behave
as oncogenes (red) or tumor suppressors (green) which enable deregulation of the metabolic
regulation depicted in (B).
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FIGURE 4. Metabolic enzymes as oncogenes or tumor suppressors
A. SDH and FH can genetically behave as tumor suppressors in specific cancers. The
accumulation of succinate or fumarate that arises owing to inactivating mutations in SDH or
FH potentiates aberrant stabilization of HIF1 through competitive inhibition of PHDs. IDH
mutants arise in a fraction of gliomas, acute myeloid leukemias, and chondrosarcomas.
These mutants acquire a neomorphic enzymatic activity that enables the conversion of αKG
to 2HG, which can impair normal epigenetic regulation through competitive inhibition of
various αKG-dependent dioxygenases, including TET2 DNA hydroxylases and JmjC
histone demethylases. Recent evidence suggests that 2HG can also promote HIF1
degradation, and that both succinate and fumarate accumulation may also inhibit various
αKG-dependent dioxygenases. Further investigation into the pathophysiological role of
2HG may reveal a context-dependence to its functional role.
SDH – succinate dehydrogenase. FH – fumarate hydratase. HIF – hypoxia-inducible factor.
PHD – prolyl hydroxylase. αKG – α – ketoglutarate. 2HG – 2-hydroxyglutarate.
B. PHGDH is elevated in a fraction of malignant breast and melanoma cells. This elevation
promotes flux of glucose into the serine biosynthesis pathway. Suppression of PHGDH in
those cell lines that had elevated expression of the enzyme caused a strong decrease in cell
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proliferation and serine synthesis. Moreover, it was revealed that the serine pathway was
responsible for nearly 50% of the net conversion of glutamate to αKG for glutamine-driven
anaplerosis in these PHGDH-overexpressing cells. GLDC is overexpressed in the TIC
population of NSCLC cells. Suppression of GLDC effectively reduced proliferation in the
TICs. Among the alterations driven by enhanced GLDC expression in these cells was an
increase in pyrimidine biosynthesis, which made these cells particularly sensitive to
treatment with low doses of the antimetabolite methotrexate.
PHGDH – 3-phosphoglycerate dehydrogenase. GLDC – glycine decarboxylase. NSCLC –
non-small cell lung cancer. TIC – tumor-initiating cell.
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Figure 5. Application and Integration of Tools to study Tumor Metabolism
The exploitation and integration of various components of the omics cascade can provide a
new depth of insight into the study of tumor metabolism. Moreover, these approaches can be
employed not only for the interrogation of cell lines in culture, but can also be incorporated
with in vivo systems used to better model human metabolism.
Cantor and Sabatini Page 35
Cancer Discov. Author manuscript; available in PMC 2013 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. Unraveling Metabolic Diversity
The commonality of metabolic rewiring in tumor cells is that the sum of alterations and
adaptations must ultimately provide a means to support the various demands of cell
proliferation. However, the proliferative solution arises in an integrated response to some
combination of genetic and non-genetic determinants, which in turn, dictate the precise
metabolic signature and dependencies of a given tumor cell. A better understanding of this
heterogeneity should promote the continued development of therapeutic strategies that best
exploit metabolic liabilities while achieving maximal therapeutic windows.
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